JP2020519676A5 - - Google Patents

Download PDF

Info

Publication number
JP2020519676A5
JP2020519676A5 JP2019563255A JP2019563255A JP2020519676A5 JP 2020519676 A5 JP2020519676 A5 JP 2020519676A5 JP 2019563255 A JP2019563255 A JP 2019563255A JP 2019563255 A JP2019563255 A JP 2019563255A JP 2020519676 A5 JP2020519676 A5 JP 2020519676A5
Authority
JP
Japan
Prior art keywords
acting
long
receptor agonist
less
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019563255A
Other languages
English (en)
Japanese (ja)
Other versions
JP7316222B2 (ja
JP2020519676A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/032817 external-priority patent/WO2018213341A1/en
Publication of JP2020519676A publication Critical patent/JP2020519676A/ja
Publication of JP2020519676A5 publication Critical patent/JP2020519676A5/ja
Priority to JP2023063333A priority Critical patent/JP7772733B2/ja
Application granted granted Critical
Publication of JP7316222B2 publication Critical patent/JP7316222B2/ja
Priority to JP2025076268A priority patent/JP2025111770A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019563255A 2017-05-15 2018-05-15 長時間作用型インターロイキン-15受容体作動薬並びに関連する免疫治療組成物及び方法 Active JP7316222B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023063333A JP7772733B2 (ja) 2017-05-15 2023-04-10 長時間作用型インターロイキン-15受容体作動薬並びに関連する免疫治療組成物及び方法
JP2025076268A JP2025111770A (ja) 2017-05-15 2025-05-01 長時間作用型インターロイキン-15受容体作動薬並びに関連する免疫治療組成物及び方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762506494P 2017-05-15 2017-05-15
US62/506,494 2017-05-15
US201762536966P 2017-07-25 2017-07-25
US62/536,966 2017-07-25
US201762582186P 2017-11-06 2017-11-06
US62/582,186 2017-11-06
US201862648240P 2018-03-26 2018-03-26
US62/648,240 2018-03-26
PCT/US2018/032817 WO2018213341A1 (en) 2017-05-15 2018-05-15 Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023063333A Division JP7772733B2 (ja) 2017-05-15 2023-04-10 長時間作用型インターロイキン-15受容体作動薬並びに関連する免疫治療組成物及び方法

Publications (3)

Publication Number Publication Date
JP2020519676A JP2020519676A (ja) 2020-07-02
JP2020519676A5 true JP2020519676A5 (https=) 2021-07-26
JP7316222B2 JP7316222B2 (ja) 2023-07-27

Family

ID=64274790

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019563255A Active JP7316222B2 (ja) 2017-05-15 2018-05-15 長時間作用型インターロイキン-15受容体作動薬並びに関連する免疫治療組成物及び方法
JP2023063333A Active JP7772733B2 (ja) 2017-05-15 2023-04-10 長時間作用型インターロイキン-15受容体作動薬並びに関連する免疫治療組成物及び方法
JP2025076268A Pending JP2025111770A (ja) 2017-05-15 2025-05-01 長時間作用型インターロイキン-15受容体作動薬並びに関連する免疫治療組成物及び方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023063333A Active JP7772733B2 (ja) 2017-05-15 2023-04-10 長時間作用型インターロイキン-15受容体作動薬並びに関連する免疫治療組成物及び方法
JP2025076268A Pending JP2025111770A (ja) 2017-05-15 2025-05-01 長時間作用型インターロイキン-15受容体作動薬並びに関連する免疫治療組成物及び方法

Country Status (10)

Country Link
US (2) US12036283B2 (https=)
EP (1) EP3624827A4 (https=)
JP (3) JP7316222B2 (https=)
KR (2) KR20250057110A (https=)
CN (2) CN111093688B (https=)
AU (2) AU2018270926C1 (https=)
CA (1) CA3060410A1 (https=)
IL (2) IL270634B2 (https=)
MX (2) MX2019013621A (https=)
WO (1) WO2018213341A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3100005A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
AU2019271148B9 (en) 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
WO2020097556A1 (en) * 2018-11-09 2020-05-14 Nektar Therapeutics Long-acting interleukin-15 receptor agonist in combination with another pharmacologically active agent
WO2020206395A1 (en) * 2019-04-05 2020-10-08 Nektar Therapeutics Method for enhancing cellular immunotherapy
KR20220023988A (ko) 2019-05-14 2022-03-03 웨어울프 세라퓨틱스, 인크. 분리 모이어티 및 이의 사용 방법
US20220241375A1 (en) 2019-05-20 2022-08-04 Cytune Pharma Il-2/il-15r beta gamma agonist dosing regimens for treating cancer or infectious diseases
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes
MX2023004880A (es) 2020-10-26 2023-05-11 Cytune Pharma AGONISTA DE IL-2/IL-15RßY PARA EL TRATAMIENTO DE CÁNCER DE PIEL QUE NO ES MELANOMA.
EP4232069A1 (en) 2020-10-26 2023-08-30 Cytune Pharma Il-2/il-15rbetagamma agonist for treating squamous cell carcinoma
CN117597355A (zh) 2021-06-23 2024-02-23 赛腾制药 白细胞介素15变体
US20240350589A1 (en) 2021-08-13 2024-10-24 Cytune Pharma Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer
KR20250144433A (ko) * 2023-02-14 2025-10-10 아크론 바이오프로덕츠 엘엘씨 생체내 이용을 위한 인터루킨 제형물
EP4694916A1 (en) 2023-04-14 2026-02-18 SOTIO Biotech Inc. Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
EP0728210B1 (en) 1993-11-12 2005-04-13 Gilead Sciences, Inc. Thrombin mutants
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
PT772624E (pt) 1994-04-06 2001-03-30 Immunex Corp Interleucina-15
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US7008624B1 (en) 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
DK1411075T3 (da) 1998-03-12 2008-10-27 Nektar Therapeutics Al Corp Fremgangsmåde til fremstilling af polymerkonjugater
WO2001062827A2 (en) 2000-02-22 2001-08-30 Shearwater Corporation N-maleimidyl polymer derivatives
NZ541122A (en) 2002-12-26 2008-09-26 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
WO2004060965A2 (en) 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
EP1581582B2 (en) 2003-01-06 2017-06-07 Nektar Therapeutics Thiol-selective water-soluble polmer derivatives
US7276478B2 (en) 2003-09-25 2007-10-02 Zymogenetics, Inc. Methods of treating autoimmune diseases using IL-21
US20060057680A1 (en) 2004-08-11 2006-03-16 Zheng Xin X Mutant interleukin-15 polypeptides
JP2008515896A (ja) 2004-10-05 2008-05-15 オクスナー クリニック ファウンデーション Il−15によるb細胞増殖の増強
US20060257361A1 (en) 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
BRPI0611872B8 (pt) 2005-06-16 2021-05-25 Nektar Therapeutics reagente polimérico, conjugado, método para preparação de um conjugado e composição farmacêutica
KR101508621B1 (ko) 2007-02-28 2015-04-07 세리나 쎄라퓨틱스, 인코포레이티드 활성화된 폴리옥사졸린 및 이를 포함하는 조성물
MX2010008024A (es) 2008-02-01 2010-12-21 Ascendis Pharma As Profarmaco que comprende un enlazador que se puede separar por si mismo.
EP2341942A1 (en) 2008-09-19 2011-07-13 Nektar Therapeutics Polymer conjugates of therapeutic peptides
CA2740904C (en) 2008-10-21 2019-01-15 Baxter International Inc. Methods for determining active ingredients in pro-drug peg protein conjugates with releasable peg reagents (in vitro de-pegylation)
DK2598172T3 (da) 2010-07-30 2019-07-01 Baxalta GmbH Nukleofile katalysatorer til oximforbindelse
ES2866674T3 (es) 2010-11-12 2021-10-19 Nektar Therapeutics Conjugados de una fracción de IL-2 y un polímero
CN102145178B (zh) * 2011-04-15 2012-09-26 北京凯因科技股份有限公司 Peg化白介素15
WO2013020079A2 (en) 2011-08-04 2013-02-07 Nektar Therapeutics Conjugates of an il-11 moiety and a polymer
WO2014201378A1 (en) 2013-06-13 2014-12-18 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il -2 and adoptive cell therapy
MA39711A (fr) 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
WO2016060996A2 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
AU2016335860B2 (en) 2015-10-08 2023-08-10 Nektar Therapeutics Combination of an IL-2Rbeta-selective agonist and a long-acting IL-15 agonist

Similar Documents

Publication Publication Date Title
JP2020519676A5 (https=)
US8945527B2 (en) Degradable compounds and methods of use thereof, particularly with particle replication in non-wetting templates
JP2021515083A5 (https=)
JP2019534308A5 (https=)
JP2020063241A5 (https=)
JP2020537501A5 (https=)
US20130331517A1 (en) Novel Polymer Derivative Of Cytidine Metabolic Antagonist
JP2017526704A5 (https=)
Xu et al. Immunologically effective poly (D-lactic acid) nanoparticle enhances anticancer immune response
JP2015532295A5 (https=)
JP2012532185A5 (https=)
JP2011530597A5 (https=)
JP2006508091A5 (https=)
CN1708540A (zh) 喜树碱的高分子衍生物
JP2010531879A5 (https=)
CN111514306B (zh) 一种增强抗肿瘤免疫治疗的富勒烯纳米颗粒
KR20210142663A (ko) 암을 치료하기 위하여 iRGD와 공동 투여되는 저용량 사이토카인
JP2020515688A5 (https=)
US9890245B2 (en) Stearic acid derivatives and oleic acid derivatives of multi-arm polyethylene glycol
JP2018530568A5 (https=)
JP5505261B2 (ja) 薬物伝達用ポリ(アミドアミン)オリゴマーヒドロゲルおよびそれを用いた薬物伝達体
JP2018530525A5 (https=)
AU2019392742B2 (en) Anti-cancer activity of adamantane derivatives
JP2011527340A5 (https=)
CA2608463C (en) Compounds, compositions containing such compounds, and methods of treatment of metastatic melanoma and other cancers